Evoke Pharma Expands IP Portfolio with Addition of Canadian Patent Covering GIMOTI Method of Use Read more about Evoke Pharma Expands IP Portfolio with Addition of Canadian Patent Covering GIMOTI Method of Use
Evoke Pharma Announces Approval of GIMOTI® to Florida State Medicaid Program Read more about Evoke Pharma Announces Approval of GIMOTI® to Florida State Medicaid Program
Evoke Pharma Regains Compliance with Nasdaq Listing Requirements and Provides Financial Update Read more about Evoke Pharma Regains Compliance with Nasdaq Listing Requirements and Provides Financial Update
Real-World Data Analysis Reveals a Lower Risk of Tardive Dyskinesia (TD) with Metoclopramide than Previously Reported Read more about Real-World Data Analysis Reveals a Lower Risk of Tardive Dyskinesia (TD) with Metoclopramide than Previously Reported
Patient Experience Survey Reported Positive Findings for GIMOTI® Read more about Patient Experience Survey Reported Positive Findings for GIMOTI®
Evoke Pharma to Present at H.C. Wainwright Global Investment Conference Read more about Evoke Pharma to Present at H.C. Wainwright Global Investment Conference
Evoke Pharma Reports First Quarter 2022 Financial Results Read more about Evoke Pharma Reports First Quarter 2022 Financial Results
Evoke Pharma to Report First Quarter 2022 Financial Results on May 10, 2022 Read more about Evoke Pharma to Report First Quarter 2022 Financial Results on May 10, 2022
Evoke Pharma Granted FDA Market Exclusivity for GIMOTI® Read more about Evoke Pharma Granted FDA Market Exclusivity for GIMOTI®
Evoke Pharma Announces Approval of GIMOTI® to the Texas Medicaid Preferred Drug List Read more about Evoke Pharma Announces Approval of GIMOTI® to the Texas Medicaid Preferred Drug List